Cellectis Stock Surges After FDA Grants Rare Designation

Shares of Cellectis (NASDAQ: CLLS) climbed in recent trading following the U.S. Food and Drug Administration’s decision to grant Orphan Drug Designation to one of the company’s innovative gene-editing therapy candidates. This regulatory milestone provides Cellectis with significant incentives, including tax credits and potential market exclusivity, as it advances its pipeline of allogeneic CAR-T cell therapies. Investors have reacted positively to the news, viewing the FDA recognition as a vote of confidence in the biotech firm’s proprietary gene-editing platform and its potential to address unmet medical needs in oncology.